metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced RCC (mRCC) - 2nd line (L2) 2
sarcomas
thyroid cancer
urothelial cancer (UC) - bladder cancer (BC)

All treatments
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus SoC
avelumab based treatment
avelumab alone
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab

versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs gemcitabine plus platin
vs Standard of Care (SoC)
vs placebo plus SoC
vs non active control
vs BSC
vs no additional treatment
vs placebo

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open